The main aim of the project is the R&D of novel radiopharmaceuticals based on terbium-161 and novel vectors for targeted therapy of tumors. The advantage of Tb-161 is in the emission of large numbers of low energy electrons followed by gamma radiation allowing tomographic imaging and therapy follow-up. This will allow targeting of single cancer cells, micrometastases and whole tumors, particularly in early stages of diseases to increase the treatment efficiency. Project results include not only the Tb-161 production in relevant quantity, but also novel targeting molecules (see project results). Collaboration between the Czech and Norway highly experienced partners in the research, development and commercialization of the results has all prerequisites to reach the proposed results.
The project is co-financed with the state with the support of the Technology Agency of the Czech Republic within the KAPPA Programme financed by EEA and Norway funds.
- Principal investigator: Assoc. Proff. RNDr. Ján Kozempel, Ph.D.
- Solution period: 01/01/2021 - 01/04/2024
- Provider: Technology Agency of the Czech Republic
- Programme: KAPPA
- Call for proposals: STA02019TO010
- Contest type: VS - Public tender
- Contract ID: TO01000074 - Smlouva o poskytnutí podpory
- Total approved costs: 37,994 thou. CZK
- Public financial support: 33,897 thou. CZK
- Other public sources: 0 thou. CZK
- Non public and foreign sources: 4,098 thou. CZK
- R&D category: AP - Applied research
- OECD FORD - main branch: 10402 - Inorganic and nuclear chemistry
- OECD FORD - secondary branch: 30107 - Medicinal chemistry
- OECD FORD - another secondary branch: 30224 - Radiology, nuclear medicine and medical imaging
- CEP - equivalent branches (according to the converter): CA - Inorganic chemistry, CH - Nuclear and quantum chemistry, photo chemistry, FP - Other medical fields